Development and validation of a novel nomogram for pretreatment prediction of liver metastasis in pancreatic cancer

Shangxiang Chen | Shaojie Chen | Guoda Lian | Yaqing Li | Xijiu Ye | Jinmao Zou | Ruomeng Li | Ying Tan | Xuanna Li | Mengfei Zhang | Chunyu Huang | Chengzhi Huang | Qiubo Zhang | Kaihong Huang | Yinting Chen

1Department of Gastroenterology and the Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, P.R. China
2Department of Endoscopy, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, P.R. China
3Department of General Surgery, Guangdong General Hospital, Guangzhou, P.R. China
4Department of Anesthesiology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, P.R. China
5Department of Gastroenterology, Lihuili Hospital of Ningbo Medical Center, Ningbo, China

Correspondence
Kaihong Huang and Yinting Chen, Department of Gastroenterology and the Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, P.R. China.
Email: huangkh@mail.sysu.edu.cn (K. H.) and chenyt58@mail.sysu.edu.cn (Y. C.)

Funding information
This study was supported and funded by the National Natural Science Foundation of China (Grant No. 81572396, 81672408, 81874057, 81972741), and Medical Science Foundation of Sun Yat-sen University (Grant No. 19ykpy109). Grant [2013]163 from Key Laboratory of Malignant Tumor Molecular Mechanism and Translational Medicine of Guangzhou Bureau of Science and Information Technology; Grant KLB09001 from the Key Laboratory of Malignant Tumor Gene Regulation and Target Therapy of Guangdong Higher Education Institutes. Ningbo Natural Science Foundation (grant number 2016A610189); Department of

Abstract
Purpose: The diagnostic value of nomogram in pancreatic cancer (PC) with liver metastasis (PCLM) is still largely unknown. We sought to develop and validate a novel nomogram for the prediction of liver metastasis in patients with PC.

Method: About 604 pathologically confirmed PC patients from the Sun Yat-sen University Cancer Center (SYSUCC) between July, 2001 and December, 2013 were retrospectively studied. The SYSUCC cohort was randomly assigned to as the training set and internal validation set. Using these two sets, we derived and validated a prognostic model by using concordance index and calibration curves. Another two independent cohorts between August, 2002 and December, 2013 from the Sun Yat-sen Memorial Hospital (SYSMH, n = 335) and Guangdong General Hospital (GDGH, n = 503) was used for external validation.

Result: Computed tomography (CT) reported liver metastasis status, carcinoembryonic antigen (CEA) level and differentiation type were identified as risk factors for PCLM in the training set. The final diagnostic model demonstrated good calibration and discrimination with a concordance index of 0.97 and had a robust internal validation. The score ability to diagnose PCLM was further externally validated in SYSMH and GDGH with a concordance index of 0.93. The model showed better calibration and discrimination than CT, CEA and differentiation in each cohort.

Shangxiang Chen, Shaojie Chen and Guoda Lian have contributed equally to this manuscript.

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

© 2020 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
INTRODUCTION

Pancreatic ductal adenocarcinoma (PDAC) is among the most deadly cancers with a 5-year survival rate of less than 6%, for its aggressive metastatic nature. A preliminary analysis of 1620 PDAC cases from the Guangdong Province of China identified that 54.4% of the PDACs were diagnosed with distant metastasis, and more than half of which were liver metastases. Also, recent studies have reported that a large proportion of PDACs had liver metastasis at their initial diagnosis. As such, the accurate identification of liver metastasis is crucial for guiding strategic treatment decisions and prognostic assessments. Therefore, effective and easily accessible approach methods are urgently needed for the prediction and diagnosis of liver metastasis in PDAC patients.

Currently, histopathologic examination and imaging modalities such as computed tomography (CT) are the mostly commonly methods used to diagnose liver metastasis. However, the accuracy of preoperative histopathologic examinations is largely dependent on the quality of the punctured tissues. In addition, solely relying on CT scans has also been reported to be insufficient to accurately identify malignant lesions. To improve the sensitivity and specificity of each method, the advantages of these biomarkers (such as imaging features, histopathologic examination, and blood index values) should be incorporated. To analyze a panel of effective biomarkers as a group is the most promising method to change clinical management. To our knowledge, there is no literature reporting on a preoperative signature to improve the diagnosis of liver metastasis in PDAC patients.

Data collection

Patient and tumor related variables such as host status (i.e., age, gender), primary tumor characteristics (i.e., site, differentiation, carcinoembryonic antigen (CEA) level, carbohydrate antigen 19-9 (CA19-9) level, alpha-fetoprotein (AFP) level, CT-reported liver metastasis), and follow-up data were reviewed. The level of CEA, CA19-9, and AFP was obtained via laboratory analysis of the patients’ routine blood test at initial diagnosis, and the cutoff value was determined by the Youden-index method. The tumor site was defined as head, body, tail, and overlapping lesions based on the location of the center of the lesion. As for the tumor differentiation type, well and moderately differentiated type were defined as the differentiated type, while the poorly differentiated were defined as the undifferentiated type. The CT diagnosis of pancreatic cancer (PC) with liver metastasis (PCLM) was performed by at least two radiologists to avoid the bias.

Constructing nomogram

The Primary dataset was randomly divided by computer-aid into two groups, namely the Training and Internal validation dataset. Selection bias regarding the factors for the random classification into the two groups was adjusted. Lasso Cox regression analysis was used in the training set to identify the independent risk factors, based on which the nomogram was constructed.

Conclusion: Based on a large multi-institution database and on the routinely observed CT-reported status, CEA level and tumor differentiation in clinical practice, we developed and validated a novel nomogram to predict PCLM.

KEYWORDS
diagnosis, liver metastasis, nomogram, pancreatic cancer
2.4 | Validating nomogram

Discrimination and calibration analysis were performed to evaluate performance of the nomogram in the training (SYSUCC, n = 302) and two other independent datasets (SYSMH, n = 335 and GDGH, n = 503). The Harrell’s C-index was used for the discrimination analysis.10,11 The C-index provides the probability between the observed and predicted probability of PDAC with liver metastasis. The C-index could work as a measure of the accuracy of a nomogram.12 For the calibration of the nomogram, data were grouped based on the probabilities calculated by the nomogram predictive model. The predicted probabilities produced was then compared with the actual probabilities. H-L chi-square statistic and bootstrapping correction were used.13

Analysis were completed using the software statistical package for social sciences version 20.0 (SPSS, Chicago, IL) and the package of glmnet in R software version 3.5.1 (http://www.r-project.org/). P < .05 was considered as statistically significant.

2.5 | Clinical applicability of the nomogram

To assess the clinical usefulness of the nomogram, decision curve analysis was performed. The net benefits at different

| TABLE 1 | Clinical features of primary training set and validation set |
|-----------------------|-----------------------|-----------------------|-----------------------|
|                        | Training set (n = 302) | Validation set (n = 302) |
| Age (y)                | LM (+) | LM (−) | LM (+) | LM (−) | P          |
| <61                    | 61 (55.5) | 112 (58.3) | 56 (53.8) | 116 (58.6) | .934       |
| ≥61                    | 49 (44.5) | 80 (41.7)  | 48 (46.2) | 82 (41.4)  |            |
| Gender                 |         |         |         |         |            |
| Male                   | 74 (67.3) | 130 (67.7) | 69 (66.3) | 131 (66.2) | .729       |
| Female                 | 36 (32.7) | 62 (32.3)  | 35 (33.7) | 67 (33.8)  |            |
| Primary site           |         |         |         |         |            |
| Head                   | 50 (45.5) | 129 (67.2) | 43 (41.3) | 129 (65.2) | .133       |
| Body                   | 7 (6.4) | 16 (8.3)  | 16 (15.4) | 23 (11.6)  |            |
| Tail                   | 22 (20.0) | 12 (6.3)  | 22 (21.2) | 14 (7.1)   |            |
| Overlapping lesions    | 31 (28.1) | 35 (18.2)  | 23 (22.1) | 32 (16.1)  |            |
| Differentiation        |         |         |         |         |            |
| Differentiated         | 18 (16.4) | 95 (49.5)  | 23 (22.1) | 89 (44.9)  | .933       |
| Undifferentiated       | 92 (83.6) | 97 (50.5)  | 81 (77.9) | 109 (55.1) |            |
| CEA level (ng/mL)      |         |         |         |         |            |
| <4.5                   | 33 (30.0) | 83 (43.2)  | 40 (38.5) | 88 (44.4)  | .098       |
| ≥4.5                   | 77 (70.0) | 69 (35.9)  | 64 (61.5) | 86 (43.4)  |            |
| Unknown                | 40 (20.9) |            | 24 (12.2) |            |            |
| CA19-9 level (ng/mL)   |         |         |         |         |            |
| <386.6                 | 40 (36.4) | 67 (34.9)  | 36 (34.6) | 77 (88.9)  | .432       |
| ≥385.6                 | 63 (57.3) | 74 (38.5)  | 57 (54.8) | 86 (43.4)  |            |
| Unknown                | 7 (6.3) | 51 (26.6)  | 11 (10.6) | 35 (17.7)  |            |
| AFP level (ng/mL)      |         |         |         |         |            |
| <2.84                  | 36 (32.7) | 39 (20.3)  | 31 (29.8) | 48 (24.3)  | .374       |
| ≥2.84                  | 28 (25.5) | 35 (18.2)  | 28 (26.9) | 47 (23.7)  |            |
| Unknown                | 46 (41.8) | 118 (61.5) | 45 (43.3) | 103 (52.0) |            |
| CT-reported LM status  |         |         |         |         |            |
| Positive               | 93 (84.5) | 5 (2.6)   | 87 (83.7) | 2 (1.0)    | .428       |
| Negative               | 17 (15.5) | 187 (97.4) | 17 (16.3) | 196 (99.0) |            |

Abbreviations: AFP, alpha fetoprotein; CA19-9, carbohydrate antigen 19-9; CEA, carcinoembryonic antigen; LM, liver metastasis.
threshold probabilities were quantified as per previously described.14

3 | RESULTS

3.1 | Patient demographics and outcomes

The data of the PCLM patients from the training (n = 302) and internal validation set (n = 302) were analyzed and no selective bias or significant difference in the investigated features between both groups was found (all \( P > .05 \)). The clinicopathologic features for the training and internal validation group are showed as Table 1. There were 129 and 130 patients who were \( \geq 61 \) years old in training set and validation set separately. About 204 male in the training set and 200 male in the validation set. There were 110 and 104 PDAC with liver metastasis in the training and validation set, respectively, and the baseline clinical features for the two external validations are presented in Table 2.

3.2 | Risk factors screening

Factors were transformed and examined to fit the Logistic Regression.9,15 Lasso Cox Regression was used to select the most useful clinical features for the diagnosis of PCLM in the training set. CEA level, tumor differentiation type and

| TABLE 2 | Clinical features of SYSMH set and GDGH set |
|-----------------|-----------------|-----------------|-----------------|-----------------|
|                | SYSMH set (n = 335) | GDGH set (n = 503) |                |
|                | LM (+) | LM (−) | LM (+) | LM (−) | LM (+) | LM (−) |                |
| Age (y)        |        |        |        |        |        |        |                |
| < 61           | 13 (48.1) | 185 (55.1) | 68 (38.9) | 121 (36.9) |        |        |                |
| \( \geq 61 \)  | 14 (51.9) | 151 (44.9) | 107 (61.1) | 207 (63.1) |        |        |                |
| Gender         |        |        |        |        |        |        |                |
| Male           | 12 (44.4) | 229 (68.2) | 115 (65.7) | 195 (40.5) |        |        |                |
| Female         | 15 (55.6) | 107 (31.8) | 60 (34.3) | 133 (59.5) |        |        |                |
| Primary site   |        |        |        |        |        |        |                |
| Head           | 11 (40.7) | 40 (11.9) | 75 (42.9) | 210 (64.0) |        |        |                |
| Body           | 3 (11.1) | 88 (26.2) | 19 (10.9) | 26 (7.9) |        |        |                |
| Tail           | 5 (18.5) | 71 (21.1) | 38 (21.7) | 29 (8.8) |        |        |                |
| Overlapping lesions | 8 (29.6) | 137 (40.8) | 43 (24.6) | 63 (19.2) |        |        |                |
| Differentiation|        |        |        |        |        |        |                |
| Differentiated | 7 (25.9) | 15 (4.5) | 43 (24.6) | 104 (31.7) |        |        |                |
| Undifferentiated | 20 (74.1) | 321 (95.5) | 132 (75.4) | 224 (68.3) |        |        |                |
| CEA level (ng/mL) |        |        |        |        |        |        |                |
| < 4.5          | 11 (40.7) | 83 (24.7) | 55 (31.4) | 179 (54.6) |        |        |                |
| \( \geq 4.5 \) | 14 (51.9) | 33 (9.8) | 113 (64.6) | 121 (36.9) |        |        |                |
| Unknown        | 2 (7.4) | 220 (65.5) | 28 (8.5) |        |        |        |                |
| CA19-9 level (ng/mL) |        |        |        |        |        |        |                |
| < 386.6        | 14 (51.9) | 86 (25.6) | 63 (36.0) | 173 (52.7) |        |        |                |
| \( \geq 385.6 \) | 11 (40.7) | 30 (8.9) | 101 (57.3) | 134 (40.9) |        |        |                |
| Unknown        | 2 (7.4) | 220 (65.5) | 11 (6.3) | 21 (6.4) |        |        |                |
| AFP level (ng/mL) |        |        |        |        |        |        |                |
| < 2.84         | 16 (59.3) | 68 (20.2) | 67 (38.3) | 130 (39.6) |        |        |                |
| \( \geq 2.84 \) | 9 (33.3) | 39 (11.6) | 94 (53.7) | 156 (47.6) |        |        |                |
| Unknown        | 2 (7.4) | 229 (68.2) | 14 (8.0) | 42 (12.8) |        |        |                |
| CT-reported LM status |        |        |        |        |        |        |                |
| Positive       | 25 (92.6) | 5 (2.6) | 150 (85.7) | 3 (0.9) |        |        |                |
| Negative       | 2 (7.4) | 184 (97.4) | 25 (14.3) | 325 (99.1) |        |        |                |

Abbreviations: AFP, alpha fetoprotein; CA19-9, carbohydrate antigen 19-9; CEA, carcinoembryonic antigen; LM, liver metastasis.
CT-reported LM status were identified as the independent risk factors for PDAC with liver metastasis (Figure 1).

### 3.3 Construction and validation of the nomogram

A nomogram comprising of the CEA level, tumor differentiation type and CT-reported LM status was constructed based on the independent risk factors identified in training set. As illustrated in Figure 2, by adding up the points identified on the points scale, the nomogram can provide the risk for a PDAC patient to be diagnosed with liver metastasis. The C-index for this nomogram (0.970) was superior to that of CT estimation alone (0.930), tumor differentiation type (0.680), and CEA level (0.670). Similar results were obtained upon analysis in the internal validation dataset (C-index: nomogram, 0.930; CT estimation, 0.920; tumor differentiation type, 0.620; CEA level, 0.540) and the primary dataset (C-index: nomogram, 0.940; CT estimation, 0.920; tumor differentiation type, 0.630; CEA level, 0.580). The C-index for the model (0.930) also exhibited superior to the CT (0.920), CEA level (0.480), and differentiation (0.550) in the validation set. The nomogram

![Figure 1](image_url)  
**Figure 1** Clinicopathological features selection using the least absolute shrinkage and selection operator (LASSO) binary logistic regression model. A. Tuning parameter (λ) selection in the LASSO model used a 10-fold cross-validation via minimum criteria. The dotted vertical lines were drawn at the optimal values by using the minimum criteria and the 1 standard error of the minimum criteria (the 1-SE criteria). B. Illustrate the LASSO coefficient profiles of the pancreatic cancer with liver metastasis-associated clinical features. A coefficient profile plot was produced against the log (λ) sequence. A vertical line was drawn at the value selected chosen by 10-fold cross-validation.
has the optimal C-index value in the primary set as well (0.940).

Further, the calibration of the three different datasets mentioned above was then performed. As illustrated in Figure 3, the apparent line was very close to that of the ideal line of liver metastasis, demonstrating reliable calibration for predicting the probability of PDAC with liver metastasis.

In the SYSM and GDGH external validation set, the C-index of the nomogram (0.934) was also superior to that of the CT estimation (0.923), tumor differentiation type (0.513), and CEA level (0.644). Subsequently, the PDAC LM-predictive nomogram maintained an optimal calibration and discrimination, as presented in Figure 3D.

Further, as an estimation for the clinical reliability and practicability of this nomogram, we compared the efficiency between the nomogram and the individual variables by ROC curves. The nomogram consistently demonstrated the largest AUC value both in the training set (0.954), the internal validation set (0.924), and also upon external validation (0.934) (Figure 4).

### 3.4 Clinical use

The decision curve analysis for our nomogram and the individual factors (CT, CEA level, and differentiation) are presented in Figure 5. As shown in figure, if the threshold probability of a patient or doctor is > 10%, our nomogram adds more benefit to predict PCLM than all the individual factors.

## 4 DISCUSSION

In present study, using a large multi-center population, we have developed and validated a pretreatment risk estimation nomogram for the prediction of liver metastasis in patients with PDAC. Three basic and routinely used clinicopathological features, namely the use of radiographic CT for the estimation of liver metastasis, CEA level and the tumor differentiation type were observed to be independent factors in the training set and incorporated into the nomogram. This risk estimation nomogram demonstrated reliable and consistent results upon both internal and external validation. As such, this novel nomogram-based model could stratify PDCA patients by predicting their risk of liver metastasis with high accuracy and may provide a more accurate approach for guiding individualized pretreatment therapeutic decisions.

CEA has been reported to have a low sensitivity of 39.5%, but acceptable specificity of 81.3% as a biomarker in PC. A previous study has showed that the CEA level was a reliable prognostic predictor in PDAC patients. Elevated levels of CEA were associated with poor prognosis for patients with PC. However, until now, there have been no literature revealing the importance of the status of CEA level in the diagnosis of PCLM. The predictive value of the use of radiographic imaging via CT scans and tumor differentiation type in the diagnosis of PCLM were also not well described. Since these are clinically important and reliable methods routinely used in clinical practice to help diagnosis of PCLM, their combined use to build
this risk-predictive nomogram makes it clinically practical to serve as a more reliable approach for the diagnosis of PCLM.

Nomogram has been reported to be a novel tool for survival prediction in PC previously. However, it has not been applied in the diagnosis of PCLM yet. To construct a nomogram for the diagnosis of PCLM, a panel of features were incorporated into an integrated model. Actually, analysis of combined individual markers could improve the discrimination and has been widely used in recent studies. Panels of genes were identified and analyzed for their use in survival prediction. Similarly, the constructed nomogram incorporated multiple individual markers and has adequate discrimination in the training set, which was then demonstrated with good calibration and discrimination in the validation set as well. As for the comparable positivity of liver metastasis in the training and validation set, the improved calibration and discrimination indicated that the nomogram was extremely stable in the prediction of PCLM and could be used in validation set without adjusting the intercept and regression coefficients regarding the model building. Further validation was performed by two independent external validation set, which ascertained its wide application.

To validate the applicability of our model, we established and validated (by both internal and external validation) our nomogram by using a large cohort of multi-institutional data. It is unreliable to assess a nomogram just by internal validation due to the data heterogeneity. External validation could be a complement to problems mentioned above. To justify
its clinical usefulness, our nomogram was validated independently in SYSM and GDGH set to avoid selective bias and identify its universal applicability. Surprisingly, our nomogram showed satisfactory predictive value not only in training and internal validation set, but also in the external validation set. The comprehensive validations further ascertained the applicability of our model in different populations.

The most important and attracted point is the clinical use of the diagnostic model. We used the Lasso Cox Regression method to select the most useful markers of all the PCLM-associated clinical factors. The method could both select predictors on the basis of the strength of their univariable association with clinical outcome, and combine the selective predictors into an integrated model. Net benefit was also derived by the decision curve analysis method in this study, which offers us insight into the clinical benefit on the bias of threshold probability. In fact, if the threshold probability of a PDAC patient or doctor is > 10%, using the diagnostic model in predicting PCLM adds more benefit. What is more, our model identified the definite risk factors of PCLM. Clinical features such as CT, CEA level, and differentiation type were first been revealed to be associated with the occurrence of PCLM in this study. Doctors and PDAC patients should pay more attention to these high-risk factors before therapy decision. In addition, we first incorporated these valuable variables and built a nomogram. Both doctors and patients could perform an individualized pretreatment evaluation of the risk of PCLM with this easy

**FIGURE 4** The ROC curves and AUCs values in the (A) training, (B) validation, (C) primary, and (D) SYSMH + GDGH sets
to use scoring system, which may do great help in guiding personalized treatment.\textsuperscript{30}

Certainly, there are still some limitations. First, this study analyzed PDAC patients from China. Whether this model will be suitable for other populations is yet to be demonstrated. Second, this study was a retrospective study, a prospective with larger population is required to further validate the results obtained.

In summary, based on a large cohort of patients, we propose a risk estimation nomogram which has demonstrated high accuracy, in both internal and external multi-institution validation, for stratifying PDAC patients according to their probability of having PCLM based on three routinely used clinical features. In addition, this nomogram can be conveniently used in clinical practice to guide the pretreatment therapeutic selection for PDAC patients.

ACKNOWLEDGMENTS
We thank all the participants who worked for the study.

CONFLICT OF INTEREST
All authors declare no conflicts of interest.

AUTHOR CONTRIBUTIONS
Substantial contributions to the conception and design (Kaihong Huang, Yinting Chen), development of methodology (Shangxiang Chen, Shaojie Chen, Guoda Lian), acquisition of data (Yaqing Li, Xijiu Ye, Jinmao Zou, Ruomeng Li, Ying Tan, Xuannna Li, Mengfei Zhang, Chunyu Huang, Chengzhi Huang, Qiubo Zhang), analysis and interpretation of data (Shangxiang Chen), draft of the article (Shangxiang Chen, Kaihong Huang, Yinting Chen), critical revision of the article (all authors), and final approval of the version (all authors).

DATA AVAILABILITY STATEMENT
The data of this study are available upon special request to the corresponding author(s).

ORCID
Shangxiang Chen https://orcid.org/0000-0003-1161-0480
Kaihong Huang https://orcid.org/0000-0002-1164-8115
Yinting Chen https://orcid.org/0000-0002-0490-5216

REFERENCES
1. Frič P, Šedo A, Škrha J, et al. Early detection of sporadic pancreatic cancer: time for change. Eur J Gastro Hepatol. 2016;155(1):44.
2. Ryan DP, Hong TS, Bardeesy N. Pancreatic adenocarcinoma. N Engl J Med. 2014;371(11):1039-1049.
3. Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369(18):1691-1703.

FIGURE 5 Decision curve analysis for the diagnostic nomogram and the individual clinical features. The Y-axis measures the net benefit. The black line represents the diagnostic nomogram. The dark black line represents the diagnostic nomogram. The green line represents the tumor differentiation type. The blue line represents the carcinoembryonic antigen level. The red line represents the computer tomography-reported liver metastasis (LM) status. The thin black line represents the assumption that all patients have LM metastases. Middle black line represents the assumption that no patients have LM metastases. The net benefit was calculated by subtracting the proportion of all patients who are false positive from the proportion who are true positive, weighting by the relative harm of forgoing treatment compared with the negative consequences of an unnecessary treatment.
4. Hess KR, Varadharachy GR, Taylor SH, et al. Metastatic pattern in adenocarcinoma. *Cancer*. 2006;106(7):1624-1633.

5. Dighe S, Parkayastha S, Swift I, et al. Diagnostic precision of CT in local staging of colon cancers: a meta-analysis. *Clin Radiol*. 2010;65(9):708-719.

6. Croner RS, Förtsch T, Brückl WM, et al. Molecular signature for lymphatic metastasis in colorectal carcinomas. *Ann Surg*. 2008;247(5):803-810.

7. Huang Y-Q, Liang C-H, He L, et al. Development and validation of a radiomics nomogram for preoperative prediction of lymph node metastasis in colorectal cancer. *J Clin Oncol*. 2016;34(18):2157-2164.

8. Fluss R, Faraggi D, Reiser B. Estimation of the Youden Index and its associated cutoff point. *Biometrical J*. 2005;47(4):458-472.

9. Iasonos A, Schrag D, Raj GV, Panageas KS. How to build and interpret a nomogram for cancer prognosis. *J Clin Oncol*. 2008;26(8):1364-1370.

10. Harrell FE Jr, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. *Stat Med*. 1996;15(4):361-387.

11. Han D-S, Suh Y-S, Kong S-H, et al. Nomogram predicting long-term survival after d2 gastrectomy for gastric cancer. *J Clin Oncol*. 2012;30(31):3834-3840.

12. Harrell FE Jr, Califf RM, Pryor DB, Lee KL, Rosati RA. Evaluating the yield of medical tests. *JAMA*. 1982;247(18):2543-2546.

13. Song KY, Park YG, Jeon HM, Park CH. A nomogram for predicting individual survival of patients with gastric cancer who underwent radical surgery with extended lymph node dissection. *Gastric Cancer*. 2014;17(2):287-293.

14. Vickers AJ, Cronin AM, Elkin EB, Gonen M. Extensions to decision curve analysis, a novel method for evaluating diagnostic tests, prediction models and molecular markers. *BMC Med Inform Decis Mak*. 2008;8:53.

15. Balachandran VP, Gonen M, Smith JJ, Dematteo RP. Nomograms in oncology – more than meets the eye. *Lancet Oncology*. 2015;16(4):173.

16. Liang W, Zhang LI, Jiang G, et al. Development and validation of a nomogram for predicting survival in patients with resected non-small-cell lung cancer. *J Clin Oncol*. 2015;33(8):861-869.

17. Ni XG, Bai XF, Mao YL, et al. The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer. *Eur J Surg Oncol*. 2005;31(2):164-169.

18. Xu HX, Liu L, Xiang JF, et al. Postoperative serum CEA and CA125 levels are supplementary to perioperative CA19-9 levels in predicting operative outcomes of pancreatic ductal adenocarcinoma. *Surgery*. 2017;161(2):373-384.

19. Distler M, Pilarsky E, Kersting S, Grützmann R. Preoperative CEA and CA 19–9 are prognostic markers for survival after curative resection for ductal adenocarcinoma of the pancreas – a retrospective tumor marker prognostic study. *Int J Surg*. 2013;11(10):1067-1072.

20. Gu YL, Lan C, Pei H, Yang SN, Liu YF, Xiao LL. Applicative value of serum CA19-9, CEA, CA125 and CA242 in diagnosis and prognosis for patients with pancreatic cancer treated by concurrent chemoradiotherapy. *Asian Pacific J Cancer Prev Aijcp*. 2015;16(15):6569-6573.

21. Vernerey D, Huguet F, Vienot A, et al. Prognostic nomogram and score to predict overall survival in locally advanced untreated pancreatic cancer (PROLAP). *Br J Cancer*. 2016;115(3):281-289.

22. Hamada T, Nakai Y, Yasunaga H, et al. Prognostic nomogram for nonresectable pancreatic cancer treated with gemcitabine-based chemotherapy. *Br J Cancer*. 2014;110(8):1943-1949.

23. de Castro SM, Biere SS, Lagarde SM, Busch OR, van Gulik TM, Gouma DJ. Validation of a nomogram for predicting survival after resection for adenocarcinoma of the pancreas. *British J Surgery*. 2009;96(4):417-423.

24. Li X, Zhang Y, Zhang Y, Ding J, Wu K, Fan D. Survival prediction of gastric cancer by a seven-microRNA signature. *Gut*. 2010;59(5):579-585.

25. Balasenthil S, Huang Y, Liu S, et al. A plasma biomarker panel to identify surgically resectable early-stage pancreatic cancer. *J Nat Cancer Institute*. 2017;109(8).

26. Hu Z, Chen XI, Zhao Y, et al. Serum microRNA signatures identified in a genome-wide serum microRNA expression profiling predict survival of non-small-cell lung cancer. *J Clin Oncol*. 2010;28(10):1721-1726.

27. Iasonos A, Schrag D, Raj GV, Panageas KS. How to build and interpret a nomogram for cancer prognosis. *J Clin Oncol*. 2008;26(8):1364-1370.

28. Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. *N Engl J Med*. 2004;351(27):2817-2826.

29. Sparano JA, Gray RJ, Makower DF, et al. Prospective validation of a 21-gene expression assay in breast cancer. *N Engl J Med*. 2015;373(21):2005-2014.

30. Balachandran VP, Gonen M, Smith JJ, Dematteo RP. Nomograms in oncology: more than meets the eye. *Lancet Oncol*. 2015;16(4):e173-e180.

How to cite this article: Chen S, Chen S, Lian G, et al. Development and validation of a novel nomogram for pretreatment prediction of liver metastasis in pancreatic cancer. *Cancer Med*. 2020;9:2971–2980. https://doi.org/10.1002/cam4.2930